Bristol Myers Squibb is acquiring an Nvidia DGX SuperPOD built on the chipmaker's Vera Rubin architecture in a deal that will see the company become the first life sciences group to purchase one of the systems. The technology, which uses deep neural networks to analyze and simulate complex data sets, will allow the pharmaceutical giant to enhance its drug discovery and development operations.
The acquisition is part of Bristol Myers Squibb's efforts to leverage artificial intelligence in its research and development processes. By incorporating Nvidia's DGX SuperPOD into its workflow, the company aims to accelerate the identification of new treatments and improve the efficiency of its clinical trials.
Nvidia introduced the Vera Rubin architecture earlier this year, which was designed specifically for life sciences applications. The architecture uses a unique chip design that allows it to efficiently process complex data sets using deep neural networks. The acquisition is expected to have significant implications for the pharmaceutical industry, with many experts predicting that AI-powered systems will play a major role in drug discovery and development going forward.